MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Peripheral Arterial Disease

In brief

In our research, we are delving into whether taking MitoQ for six months can improve the symptoms and function of people diagnosed with peripheral artery disease, especially those who suffer from leg pain while walking, known as intermittent claudication. We will be checking if MitoQ helps people with claudication walk better, be more active every day, feel better about their lives, and if it enhances the health of their leg muscles.

Key facts

Study ID

NCT06409949

Run by

University of Nebraska

People needed

60

Starts

2023-06-01

Expected to finish

2027-06-01

Last updated by the study team

2026-02-24

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• a positive history of chronic claudication
• exercise-limiting claudication established by history and direct observation during a screening walking test administered by the evaluating vascular surgeon
• documented lower extremity arterial occlusive disease based on ankle/brachial index measurements and/or arterial imaging
• stable blood pressure, lipid and diabetes regimens and risk factor control for 6 weeks.

You may not qualify if…

• rest pain or tissue loss due to PAD (Fontaine stage III and IV)
• acute lower extremity ischemic event
• walking capacity significantly and primarily limited by conditions other than claudication including leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology.

Where it is running

• VA Medical Center — Omaha, Nebraska, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.